This trial is active, not recruiting.

Condition lung cancer
Sponsor National University Hospital, Singapore
Start date October 2005
End date December 2014
Trial identifier NCT00717353, NS05/25/04



1. To determine the presence and frequency of novel and known UGT1A6 and UGT2B7 polymorphisms in healthy Chinese, Malay and Indian subjects.

2. To determine the presence and frequency of novel and known UGT1A6 and UGT2B7 polymorphisms in Chinese lung cancer patients with squamous cell and adenocarcinoma subtype.

3. To analyze the functional variations in UGT1A6 and UGT2B7 polymorphisms.


1 To study the correlation of UGT1A6 and UGT2B7 polymorphisms with lung cancer type.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective cross-sectional
Lung cancer

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion criteria for stage I study - Subjects >= 18 years old - Hemoglobin >= 8g/dL, Total white cell counts >3.0 x 103/μl - ECOG =0 Inclusion criteria for stage II study - Chinese ethnicity - Patients >18 years old - Hemoglobin => 8g/dL, Total white cell counts >3.0 x 103/μl - Histologically or cytologically confirmed lung cancer for stage II study - Uncontrolled medical conditions such as diabetes, hypertension and coronary artery disease. Exclusion criteria - Histology of small cell lung cancer - Medical or psychiatric conditions which may impair the patient's ability to provide informed consent.

Additional Information

Official title Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype
Principal investigator Wei Peng Yong, MRCP, MB ChB
Description Germline polymorphisms are inherited genetic variation present in all cells of the body. At molecular level, such variations may affect gene transcription, translation, mRNA stability, protein activity, protein expression (1-3). Mounting evidences have emerged showing that genetic polymorphisms in drug metabolizing genes and DNA repaired genes are major determinants of response to drugs and carcinogens with possible predictive or prognostic value for clinical outcome (4-6). However, only a small number of all polymorphisms discovered have functional significance and it is often difficult to predict this base on nucleotide sequence alone. Genome based studies have generated a wealth of data on genetic polymorphisms far exceeds our knowledge on the function of these variants. Hence, there is an urgent need to characterize the functional and expressional impact of genetic polymorphisms in candidate genes so that appropriate target polymorphisms most likely to affect the phenotype can be selected for larger scale association studies. In this study, we will adopt a novel 2-stage approach to identify and characterize new polymorphisms in the UGT1A6 and 2B7 genes in our Asian population. Data from our initial genotyping work will then be used to optimize the study design of the stage II association study for the generation of hypothesis that lung cancer histology (phenotype) is associated with UGT polymorphisms (genotype). This study will help to advance our understanding in the functional significance and diversity of genetic variants that exist in our population. It may also shed light on the role of UGT in carcinogenesis and will provide vital ground work for future studies of risk assessment, treatment and may allow identification of at risk individual for chemoprevention and adjuvant therapy studies.
Trial information was received from ClinicalTrials.gov and was last updated in January 2014.
Information provided to ClinicalTrials.gov by National University Hospital, Singapore.